Bio-Thera Solutions Submits BLAs for Stelara Biosimilar BAT2206 to FDA and EMA
Bio-Thera Solutions Ltd, a biopharmaceutical company based in Guangzhou, has announced the submission of Biologic...
Biosimilars
Ocumension Therapeutics and Shandong Boan Biotechnology File for Market Approval of Biosimilar Aflibercept in China
Ocumension Therapeutics (HKG: 1477) and Shandong Boan Biotechnology Co., Ltd (HKG: 6955) have jointly announced...
U.S. Senate Passes Affordable Prescriptions for Patients Act to Limit Patent Thicketing
In a significant move to curb drug prices, the U.S. Senate unanimously passed the Affordable...
MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru
MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has...
Henlius Pharmaceutical’s HLX15 Biosimilar Meets Phase I Clinical Endpoints
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the successful completion of a Phase...
China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the...
Bio-Thera Solutions’ BAT1806 Biosimilar Receives European Commission Approval
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...
Hybio Pharmaceutical’s Biosimilar Liraglutide Gets Temporary FDA Nod Pending Patent Expiry
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...
Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval
Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...
Bio-Thera Solutions Partners with STADA for European Commercialization of Golimumab Biosimilar
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced a licensing...
3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement...
Boan Biotech’s Dulaglutide Biosimilar Accepted for Review by China’s CDE
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced that the Center...
Henlius Biotech’s Biosimilar Rituximab Receives First Overseas Marketing Approval from Peru
Shanghai Henlius Biotech Co., Ltd (HKG: 2696), a biopharmaceutical company based in China, has announced...
Boan Biotech’s Dulaglutide Biosimilar Accepted for Review by China’s CDE
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced that the Center...
Henlius Biotech’s Biosimilar Rituximab Receives First Overseas Marketing Approval from Peru
Shanghai Henlius Biotech Co., Ltd (HKG: 2696), a biopharmaceutical company based in China, has announced...
Luye Pharma’s Subsidiary Gets NMPA Green Light for Biosimilar Xgeva
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a controlling subsidiary of China-based Luye Pharma Group...
Henlius Biotech’s Denosumab Biosimilar Secures EMA Review for European Market Entry
Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...
Sandoz Receives European Commission Approval for Biosimilars Wyost and Jubbonti
The European Commission (EC) has granted registration approval to Sandoz, a Switzerland-headquartered pharmaceutical company (SWX:...